CN Menu
Press Release
Press Release
Release Date
All 2023 2022 2021 2020 2019
Nov, 2021
Shenzhen Evergreen Pharmaceutical Co., Ltd. established Hetao Laboratory
Since the first Hetao International Pharmaceutical Forum was successfully held on May 13, 2021, Dr. Du Tao, chairman of Shenzhen Evergreen Pharmaceutics Co., LTD. (hereinafter referred to as "Evergreen Pharmaceutics"), as the initiator of the forum, has been paying close attention to the development of Hetao Shenzhen-Hong Kong Science and Technology Innovation Cooperation Zone. Hetao as shenzhen and Hong Kong "bite" is extremely conducive to Chinese enterprises and international docking. At the same time, the drug audit center will be located here in the future to facilitate the development of innovative pharmaceutical research and development enterprises. Therefore, Dr. Du Tao believes that Evergreen, which has strong ability of drug innovation and development, should enter
Mar, 2021
Evergreen Therapeutics, Inc. Raised RMB 100 million in Series A Financing to Develop Covid-19 Drugs
On March 15, a fast-growing bio-innovative pharmaceutical company, Evergreen Therapeutics, announced the completion of RMB 100 million Series A financing. This round of financing was led by Shenzhen Tiantu Capital, Shenzhen Share Capital, and other investment institutions followed. The funds raised will be used to support Evergreen's new drug research and development, including phase II clinical trial of coronavirus pneumonia injection drug EG-009A and the development of other clinical phases and preclinical projects.  "Evergreen Therapeutical, Inc. received three US FDA clinical approvals in just over a year. Its success is a result of Evergreen’s professional and excellent team, and is also inseparable from the trust and support of investors." Dr. Du Tao, Chairman of Evergr
Apr, 2020
Evergreen Therapeutics, Inc. Announced to Develop EG-009 for the Treatment of Moderate to Severe COVID-19
In April 2020, Evergreen Therapeutics, Inc. announced the development of a new pipeline, EG-009, to treat the Cytokine Release Syndrome (CRS) caused by the Novel Coronavirus pneumonia. Epidemiologists predict that the world will remain in a pandemic state until June 2021. The virus continues to spread at a slow rate, and intermittent lockdowns are the new normal. It is estimated that 250 million people worldwide will be infected and 1.75 million will die by June 2021.CRS is one of the leading causes of death in COVID-19 patients. CRS is a complex inflammatory response. During the occurrence of CRS, various cytokines such as TNF-, IL-1, IL-6, IL-12, IFN-, IFN-, McP-1, and IL-8 are produced in large quantities in body fluids. CRS can cause acute respiratory distress syndrome and mu
Oct, 2021
The First Offline Meeting of Evergreen USA Team was Held to Review Achievements and Look into the Future
On October 18-19, 2021, Evergreen Therapeutics Co., Ltd. held its first offline meeting at the US headquarters since the outbreak in Bethesda, Maryland. Dr. Du Tao, Chairman of the Board, Dr. Du Xin, Chief Executive Officer, Dr. Li Changqing, Chief Medical Officer, COO Kevin Wang, CFO Julia Lu, Clinical and preclinical Division Director, senior consultant of the company and former senior FDA officer Dr. Florence Houn and other members of Evergreen's consulting team attended the meeting. Figure 1: The first meeting of Evergreen's team, department directors and consultantsUnder the chairmanship of Dr. Du Xin, the meeting reviewed the excellent achievements of Evergreen pharmaceutical in the past two years; Dr. Li Changqing, chief Medical Officer, made a systematic
Oct, 2021
FDA Experts Association Holds Autumn Gathering in Washington DC
In celebration of “Golden Autumn”, on October 16, 2021, the FDA Experts Association held the North America Golden Autumn Party at Han Palace in North Bethesda, Maryland. Since its establishment in 2019 on the bank of West Lake in Hangzhou, China, the association has grown stronger under the leadership of its presidents (first President, He Ruyi; current President, Du Tao; President-elect, Li Ning) to become a group of nearly 100 people. Members reside throughout China and the United States, with new members continuously joining, including Liu Ke (Senior VP and Director of Regulatory Affairs & Strategy at Sana Biotechnology) and Wang Yaning (CEO of Createrna Science & Technology). New members have brought fresh
Oct, 2021
Evergreen CMC Team Visits Partnership (Pii) Manufacturing Facility, to Conduct Quality Control Inspection for the Production of Anti-Coronavirus Drug
Bethesda, Maryland – October 4, 2021 – Evergreen Therapeutics announces that the CMC team, led by Evergreen CEO, Dr. Xin Du, visited its US partner, Pharmaceutics International, Inc. (Pii), and met with the project team to discuss the production of the new anti-coronavirus drug.  Dr. Du and his team visits Pii facility During the meeting, Pii’s project leader introduced and explained the company's production site via video, during which Evergreen’s CMC team discussed possible issues and solutions regarding drug production with each of Pii’s production-line teams. Thereafter, the Evergreen CMC team, guided by Pii team members, also visited several facilities, including the cGMP manufacturing area, the formulation R&D lab, and the cGMP warehouse. Evergr
Sep, 2021
Shenzhen Evergreen Therapeutics' COVID-19 Drug EG-009A has been approved for phase II clinical trials in India
Evergreen Therapeutics Inc. (hereinafter referred to as "Evergreen Therapeutics" or "Evergreen") announced on September 14, 2021 that DCGI, the Indian regulatory authority, has officially approved the phase II clinical trial of EG-009A for COVID-19 in India.EG-009A is one of Evergreen's 13 R&D pipelines and will be used to treat Cytokine Release Syndrome (CRS) caused by COVID-19 infections. India is one of the major regions where the Delta variant of COVID-19 is prevalent, and the phase II clinical trial was approved to understand the efficacy of EG-009A in patients with moderate to severe COVID-19 caused by the Delta variant. It is understood that this is the world's first clinical trial with COVID-19 Delta variant as the main research target, so it has a great clinical significan
Aug, 2021
The U.S. Food and Drug Administration (FDA) Has Approved Evergreen's EG-007 for Phase III Pivotal Clinical Trial
On August 10, 2021, Shenzhen Evergreen Pharmaceutical Co., Ltd. announced that its innovative drug candidate EG-007 has been approved by the U.S. Food and Drug Administration (FDA) to conduct a phase III pivotal clinical trial in combination with targeted drugs and anti-PD-1 antibody drugs for the treatment of advanced endometrial cancer. The primary objective of this clinical trial is to improve the therapeutic effect/response rate to immunotherapy in patients with advanced endometrial cancer by combining EG-007. The results of this phase III clinical trial will serve as a pivotal trial to provide sufficient evidence for EG-007 to receive global regulatory marketing filing (NDA) approval.  FDA approved EG-007 for phase III clinical trials in patients with advanced endometrial ca
Jul, 2021
Dr. Charles Lee Joined Evergreen Therapeutics as Chief Medical Officer
On July 19, 2021, Shenzhen Evergreen Therapeutics announced the appointment of Dr. Charles Lee as the Company's Chief Medical Officer (CMO) with overall responsibility for the Company's global drug development efforts. Dr. Lee's joining will further improve the research team building, build a more efficient clinical trial medicine system, greatly promote the progress of clinical research projects, and accelerate the leap-forward development of the company. Dr. Lee graduated from the School of Medicine of Xi 'an Jiaotong University, received his master's degree in hospital management and his doctor's degree in public health from the University of Alabama at Birmingham, USA. He worked as a resident physician at the University of Chicago Medical Center for three years, and was licensed as a physician in the United States and certified as a clinical pathologist. Dr. Lee was a senior medical reviewer of the US Food and Drug Administration (FDA), and was the first person from mainland China who studied abroad to enter FDA clinical review as a doctor. He has experience in FDA drug review and has led the development of new drugs for a number of multinational pharmaceutical companies and achieved profitable business growth. In the past four years, he is responsible for an international CRO giant in Asia Pacific, clinical, laws and regulations, market access, such as consulting, seven countries/regions in the Asia-pacific region the leadership of the team, direct management and participate in every year hundreds of R&D strategy consulting projects and help international companies of drug approval and successfully listed in China, to help domestic companies to develop global research plans to enter the international market. Dr. Lee has extensive experience in the development of new drugs in oncology, immunotherapy, anti-inflammatory, gastrointestinal and gynecological diseases, and has extensive experience in Phase I to IV clinical trials worldwide
May, 2021
"First Hetao International Medical Forum" was held in Shenzhen, Where 30 FDA Experts Led the Way to Pharmaceutical Innovation
From May 14th to May 15th, 2021, the "First Hetao International Medical Forum" was held in Shenzhen; its theme was "Focusing on the Globalization of Medicine and Building a New Height in the Industry". This conference was jointly planned and prepared by Dr. Du Tao, the sitting president of the FDA Expert Association, and professional conference agencies. The agenda of the conference covered chemical and biological drug innovation, the application of AI technology in drug development, strategies in drug clinical trial, cell and gene therapy, companion diagnostic strategies in new drug development, drug registration regulations, innovation, entrepreneurship and investment, etc. The conference also helped to build up the pharmaceutical innovation industry chain in an all-around and 19 page.tiao page.pre page 12 page page.go/